Cambridge, UK – 27 September 2023 – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.
Reflects evolution of the Company from research and development towards scale-up and commercialization
We are delighted to announce that our latest whitepaper, in collaboration with Back Bay Life Science Advisors: 'Microbiome Medicinal Products: Concept to Commercial', is now available to read and download.
Macomics Launches Super Triathlon Challenge to Raise Funds for Prof. Jeffrey Pollard Memorial Fund
Edinburgh and Cambridge, UK, 25 October 2023 – Macomics Ltd, a leader in macrophage drug discovery, is delighted to announce that it has launched the Macomics Hyper-Triathlon Challenge, in honour of its co-founder Prof. Jeffrey Pollard, who passed away earlier this year, to raise funds for the newly established Jeff Pollard’s memorial fund.
Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.
SHP2 is a tyrosine-specific phosphatase implicated in human cancers and the objective is to develop potent bifunctional compounds with excellent ADME and PK properties for efficient degradation of SHP2.
Through the collaboration, the teams have discovered unique hit compounds (profile: single-digit nM DC50 and approximately 100% Dmax) utilizing Sygnature Discovery’s innovative proprietary CHARMED technology platform.
Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
Cambridge, UK: Following the resounding success of the inaugural edition of the tech Kickstarter Competition in Jan 2023, o2h technology (a business vertical of the o2h group) is excite to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.
Following the resounding success of its inaugural edition in Jan 2023, o2h technology (a business vertical of the o2h group) is excited to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.
Click here to view the September 2023 edition of The Meeting Place!
Biocair, a distinguished life science logistics company with over three decades of expertise, was announced as the winner of two awards at the esteemed Asia-Pacific Cell & Gene Therapy Excellence Awards.
The awards ceremony, held on September 14th in Singapore, shone a spotlight on outstanding pioneers, researchers, innovators and manufacturers in the cell and gene therapy field who are fostering rapid advancements in new therapies, research and development and manufacturing processes.